Newer agents like dual GLP‐1/GIP or triple GLP‐1/GIP/Glucagon agonists will likely play an important role in the treatment of MASLD/MASH in the near future. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.